Comparative Pharmacology
Head-to-head clinical analysis: BRIELLYN versus NORQUEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIELLYN versus NORQUEST FE.
BRIELLYN vs NORQUEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
None Documented
None Documented
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Category C
Category C
Oral Contraceptive
Oral Contraceptive